4.7 Review

Clinical Use of High-Sensitivity Cardiac Troponin in Patients With Suspected Myocardial Infarction

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.07.718

关键词

algorithm; diagnostic algorithms; emergency department; high-sensitivity cardiac troponin; rule-in; rule-out

资金

  1. Swiss National Science Foundation [P300PB-167803/1]
  2. Swiss National Science Foundation
  3. Swiss Heart Foundation
  4. KTI
  5. Stiftung fur kardiovaskulare Forschung Basel
  6. Abbott
  7. Alere
  8. AstraZeneca
  9. Beckman Coulter
  10. Biomerieux
  11. BRAHMS Thermo Scientific
  12. Roche
  13. Siemens
  14. Singulex
  15. Sphingotec
  16. Department of Internal Medicine, University Hospital Basel

向作者/读者索取更多资源

High-sensitivity cardiac troponin (hs-cTn) assays have been used clinically by thousands of physicians in many countries throughout the world since their clinical introduction 7 years ago. In the early diagnosis of myocardial infarction (MI), beyond doubt, the most important indication of hs-cTn assays, these simple, inexpensive, and highly reproducible tools complement detailed clinical assessment including chest pain characteristics and the electrocardiogram. Hs-cTn assays for the first time allowed the precise quantification of cardiomyocyte injury around the 99th percentile and thereby substantially increased the accuracy of MI detection from blood obtained at presentation to the emergency department (ED). Higher accuracy at ED presentation enabled the development and extensive validation of early hs-cTn-based diagnostic algorithms, which substantially reduced the time required for the safe rule-out or rule-in of MI. This review summarizes key principles underlying the safe and effective use of hs-cTn in the ED in patients with suspected MI. (C) 2017 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据